Fig.5From: Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in ChinaAcceptability curve CE cost-effectiveness, PartSA partitioned survival analysisBack to article page